Cargando…

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor

This analysis was conducted to assess exposure–response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response Evaluation Criteria in Solid Tumors version 1.1 and longitudi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Ophelia, Zahir, Hamim, French, Jonathan, Polhamus, Daniel, Wang, Xiaoning, van de Sande, Michiel, Tap, William D., Gelderblom, Hans, Wagner, Andrew J., Healey, John H., Greenberg, Jonathan, Shuster, Dale, Stacchiotti, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592513/ https://www.ncbi.nlm.nih.gov/pubmed/34585528 http://dx.doi.org/10.1002/psp4.12712

Ejemplares similares

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020)

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
por: Lewis, James H., et al.
Publicado: (2020)

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial
por: Van De Sande, Michiel, et al.
Publicado: (2021)

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
por: Zahir, Hamim, et al.
Publicado: (2022)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
por: Monestime, Shanada, et al.
Publicado: (2020)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease
por: Healey, John H., et al.
Publicado: (2020)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature
por: Giustini, Nicholas, et al.
Publicado: (2018)

Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases
por: Mastboom, Monique J. L., et al.
Publicado: (2017)

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study
por: Bernthal, Nicholas M., et al.
Publicado: (2021)

MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment
por: Spierenburg, Geert, et al.
Publicado: (2023)

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
por: Verspoor, F. G. M., et al.
Publicado: (2019)

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
por: Gelhorn, Heather L., et al.
Publicado: (2016)

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies
por: Palmerini, Emanuela, et al.
Publicado: (2023)

A novel colony‐stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor
por: Lipplaa, Astrid, et al.
Publicado: (2023)

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
por: Benner, Brooke, et al.
Publicado: (2020)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
por: Mastboom, Monique J L, et al.
Publicado: (2017)

Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
por: van IJzendoorn, David G.P., et al.
Publicado: (2022)

The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life
por: Mastboom, Monique Josephine, et al.
Publicado: (2018)

Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2019)

Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
por: Mastboom, Monique J L, et al.
Publicado: (2018)

Localized tenosynovial giant cell tumor in children
por: Du, Xifeng, et al.
Publicado: (2023)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Tenosynovial Giant Cell Tumor Arising on the Scapular Region
por: Fukuda, Asako, et al.
Publicado: (2013)

Diffuse Type Tenosynovial Giant Cell Tumor of the Ankle
por: Zhao, Jing-Jing, et al.
Publicado: (2016)

Cryosurgery as Additional Treatment in Tenosynovial Giant Cell Tumors
por: Verspoor, F. G. M., et al.
Publicado: (2016)

Chondroid Tenosynovial Giant Cell Tumor of Temporomandibular Joint
por: Shetty, Sujeeth Kumar, et al.
Publicado: (2018)

Intramuscular Tenosynovial Giant Cell Tumor, Diffuse-Type
por: Lee, Yoo Jin, et al.
Publicado: (2016)

Tenosynovial giant cell tumor of the distal tibiofibular joint
por: Zarate, Stephanie D., et al.
Publicado: (2021)

Chondroid tenosynovial giant cell tumour of the temporomandibular joint
por: Kanbour, Abdullah, et al.
Publicado: (2021)

Tenosynovial giant cell tumor of the posterior pharyngeal space
por: Poutoglidis, Alexandros, et al.
Publicado: (2022)

Expanding the molecular spectrum of tenosynovial giant cell tumors
por: Gauduchon, Thibault, et al.
Publicado: (2022)

Tenosynovial giant cell tumor: a case report
por: Ansel, Sonam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jf8vgchkgigurt98hb0qoucn0k